Diseases [C] » Chemically-Induced Disorders [C25] » Drug-Related Side Effects and Adverse Reactions
Description
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals. MeSH
Hierarchy View
Subtype Terms (14)
Akathisia, Drug-Induced
3 drugs (2 approved, 1 experimental)
Anticholinergic Syndrome
1 approved drug
Cardiotoxicity
62 drugs (54 approved, 8 experimental)
Chemical and Drug Induced Liver Injury
32 drugs (24 approved, 8 experimental)
Chemotherapy-Related Cognitive Impairment
1 approved drug
Drug Hypersensitivity
5 drugs (4 approved, 1 experimental)
Dyskinesia, Drug-Induced
12 drugs (7 approved, 5 experimental)
Injection Site Reaction
9 drugs (7 approved, 2 experimental)
Metabolic Side Effects of Drugs and Substances
4 drugs (3 approved, 1 experimental)
Ototoxicity
14 drugs (10 approved, 4 experimental)
Serotonin Syndrome
2 approved drugs
Toxic Optic Neuropathy
1 experimental drug
Approved Indicated Drugs (1)
Phase 4 Indicated Drugs (176)
live oral poliovirus type 1, 2 and 3
measles, mumps and rubella vaccine
Phase 2 Indicated Drugs (153)
allogeneic hematopoietic stem cells (Hemacord)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous adipose-derived mesenchymal stem cells
autologous peripheral blood mononuclear cells
Phase 1 Indicated Drugs (70)
allogeneic adipose derived mesenchymal stem cell
genetically-modified neural stem cells expressing e.coli cytosine deaminase
glycerol phenylbutyrate (ravicti)
interferon gamma-1b (actimmune)
Other Experimental Indicated Drugs (88)
Organization Involved with Phase 4 Indications (33)
Organization Involved with Phase 3 Indications (21)
Organization Involved with Phase 2 Indications (42)
Chinese Academy of Medical Sciences
European Organisation for Research and Treatment of Cancer
Grupo Espanol de Investigacion en Sarcomas
Guangdong Provincial Hospital of Traditional Chinese Medicine
Herbert Irving Comprehensive Cancer Center
Infan Industria Quimica Farmaceutica Nacional
Katholieke Universiteit Leuven
Organization Involved with Phase 1 Indications (22)
Organization Involved with Other Experimental Indications (18)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.